此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment (XenCART)

2026年11月17日 更新者:Cellogen Therapeutics Pvt. Ltd.

Phase I Clinical Trial of CD20/19 Chimeric Antigen Receptor CAR T Cells in Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia or Lymphoma

XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 dose escalation design with DSMB review after each cohort will evaluate sequential dose levels of 1 2 and 4 x 10 to the power 6 CAR T cells per kg to determine the recommended Phase II dose. Dual antigen targeting is expected to reduce CD19 negative relapse which is a major limitation of single target CAR T therapy. The study will establish the safety profile of XenCART and support its further development in India.

研究概览

研究类型

介入性

注册 (估计的)

18

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Tamil Nadu
      • Vellore、Tamil Nadu、印度、632012
        • 招聘中
        • Department of Haematology A Block 5th Floor Ranipet Campus Kilminnal Village Christian Medical College Vellore Ranipet Campus
        • 接触:
        • 接触:
        • 首席研究员:
          • Dr Vikram Mathews, MBBS MD DM

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Subjects must meet ONE of the following

  1. Adults aged 18 to 65 years with relapsed or refractory CD19 and or CD20 positive B cell malignancy B ALL or B NHL
  2. B ALL At least 1 prior line of systemic therapy Ph positive ALL eligible after at least 1 BCR ABL1 TKI failure Morphological relapse with at least 5 percent blasts or MRD positive at least 10 to the power minus 4 by MFC eligible
  3. B NHL At least 2 prior lines including an anthracycline and an anti CD20 mAb At least 1 line if auto SCT ineligible or failed Transformed histologies require biopsy confirmation and prior therapy for the transformed component Refractory disease is defined as no response stable disease or progressive disease during or at the end of frontline immunochemotherapy such as R CHOP or similar OR early relapse within 3 to 12 months of end of treatment
  4. CD19 and or CD20 expression confirmed by IHC or flow cytometry on the most recent specimen within 6 months or at last relapse
  5. ECOG performance status 2 or less
  6. Adequate organ function bilirubin 1.5 times ULN or less AST ALT 3 times ULN or less creatinine 1.5 mg per dL or less or CrCl 50 mL per min or more ANC 1000 per microliter or more platelets 50000 per microliter or more LVEF 40 percent or more SpO2 92 percent or more on room air
  7. Adequate washout from prior therapy at least 2 weeks or 5 half lives whichever is shorter Anti CD20 mAb at least 4 weeks Checkpoint inhibitors at least 5 half lives
  8. Written informed consent with audio visual recording as per NDCT Rules 2019

Exclusion Criteria:

The presence of any of the following excludes enrollment

  1. Autologous SCT within 6 weeks of planned leukapheresis
  2. Prior allogeneic SCT any time
  3. Prior CAR T BiTE or other adoptive cell therapy unless CD19 or CD20 expression remains detectable on the most recent specimen
  4. Active CNS or meningeal disease prior CNS disease eligible if in remission 28 days with negative CSF
  5. Active second malignancy excluding adequately treated non melanoma skin cancer carcinoma in situ or any malignancy in CR 2 years
  6. Active HIV hepatitis B HBsAg positive hepatitis C HCV RNA detectable or tuberculosis infection
  7. Uncontrolled intercurrent illness NYHA III IV CHF LVEF less than 40 percent uncontrolled arrhythmia QTc greater than 480 ms active seizure disorder autoimmune disease on systemic immunosuppression uncontrolled hypertension or diabetes or active psychiatric illness precluding compliance
  8. Pregnancy or breastfeeding women of childbearing potential require negative beta hCG within 72 hours of leukapheresis and Day 0 infusion and effective contraception for 24 months post conditioning
  9. Active myelodysplastic syndrome therapy related MDS or therapy related AML
  10. Severe hypersensitivity to XenCAR T components lymphodepletion agents or to cilizumab not manageable with premedication

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 1.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 1 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

实验性的:Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 2.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 2 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

实验性的:Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 4.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 4 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of dose-limiting toxicities (DLT)
大体时间:Day 0 (infusion) to Day +28

Number and percentage of participants experiencing at least one DLT, as defined in the protocol, at each dose level (unit: number of participants, %).

Day 0 (infusion) to Day +28
Incidence and maximum grade of cytokine release syndrome (CRS)
大体时间:Day 0 to Day +28

Number and percentage of participants with CRS, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and maximum grade of ICANS
大体时间:Day 0 to Day +28

Number and percentage of participants with immune effector cell-associated neurotoxicity syndrome, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
大体时间:Day 0 to Month 24

Number of participants with TEAEs/SAEs, graded by CTCAE (version as per protocol) (unit: number of participants).

Day 0 to Month 24
Maximum tolerated dose (MTD) / recommended Phase 2 dose (RP2D)
大体时间:Day 0 to Day +28 of the last evaluable participant in each cohort

Highest XenCART dose level at which the DLT rate is acceptable per the dose-escalation rules, confirmed by DSMB (unit: CAR-T cells/kg).

Day 0 to Day +28 of the last evaluable participant in each cohort

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR) in B-cell NHL
大体时间:Day +28 and Day +90

Percentage of participants with complete or partial response per Lugano 2014 (PET-CT) (unit: %).

Day +28 and Day +90
Complete remission rate in B-ALL
大体时间:Day +28 (±2)

Percentage of participants with CR/CRi by bone marrow morphology (unit: %).

Day +28 (±2)
MRD-negativity rate in B-ALL
大体时间:Day +28 (±2)

Percentage of participants with MRD below 0.01% by multiparametric flow cytometry (unit: %).

Day +28 (±2)
Duration of response (DoR)
大体时间:Up to Month 24

Time from first documented response to relapse, progression or death (unit: months).

Up to Month 24
Progression-free survival (PFS)
大体时间:Up to Month 24

Time from infusion to progression, relapse or death from any cause (unit: months).

Up to Month 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dr Vikram Mathews、Christian Medical College, Vellore, India

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月26日

初级完成 (估计的)

2028年9月14日

研究完成 (估计的)

2028年9月14日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月17日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) will not be shared publicly because the study involves a limited number of participants, and sharing individual-level data may pose risks to participant privacy and confidentiality. De-identified data may be considered for sharing upon reasonable request, subject to applicable ethical, regulatory, and data protection requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅